Identification of risk factors in atypical chronic myeloid leukemia

Haematologica

Volumn 91, Issue 11, 2006, Pages 1566-1568

  Breccia, Massimo ^a,b   Biondo, Francesca ^a   Latagliata, Roberto ^a   Carmosino, Ida ^a   Mandelli, Franco ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Dept of Human Biotechnology and Hematology ^*  (Italy)

Author keywords

Atypical chronic myeloid leukaemia; Prognostic factors; Survival

Indexed keywords

BCR ABL PROTEIN;

ARTICLE; ATYPICAL CHRONIC MYELOID LEUKEMIA; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; KARYOTYPE; POLYMERASE CHAIN REACTION; RISK FACTOR; WORLD HEALTH ORGANIZATION;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 33750936737     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Galton DA. Haematological differences between chronic granulocytic leukaemia, atypical chronic myeloid leukaemia, and chronic myelomonocytic leukaemia. Leuk Lymphoma 1992;7:343-50.
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick H, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 1994;87746-54.
3. Oscier DG. Atypical chronic myeloid leukaemia, a distinct clinical entity related to the myelodysplastic syndrome? Br J Haematol 1996;92:582-6.
4. Aurich J, Duchayne E, Huget-Rigal F, Bauduer F, Navarro M, Ferel Y, et al. Clinical, morphological, cytogenetic and molecular aspects of a series of Ph-negative chronic myeloid leukemias. Hematol Cell Ther 1998;140:149-58.
5. Tefferi A, Gilliland G. Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system. Best Pract Clin Res 2006;19:365-85.
6. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
7. An International System for Human Cytogenetic Nomenclature (1985) ISCN (1978). Report of the Standing Commitee on Human Cytogenetic Nomenclature. Cytogenet Cell Genet 1985;21:309-409.
8. Cross NC, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (FCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994;8:186-90.
9. Onida F, Ball G, Kantarjian HM, Smith TL, Glassman A, Albitar M, et al. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer 2002;95:1673-84.
10. Kurzrock R, Bueso-Ramos CE, Kantarjian H, Freireich E, Tucker SL, Siciliano M, et al. BCR rearrangement-negative chronic myelogenous leukaemia revisited. J Clin Oncol 2001;19:2915-26.